| Literature DB >> 30535664 |
Rajat N Moman1,2, Stuart A Ostby1,3, Abbasali Akhoundi1,4, Rahul Kashyap1,5, Kianoush Kashani6,7,8.
Abstract
BACKGROUND: To examine the relationship between delta mean arterial pressure (ΔMAP; MAP change between pre-admission minus post-resuscitation) and acute kidney injury (AKI) among patients with septic shock. In this retrospective, single-center cohort study of adult patients pre-admission MAP is defined as the median MAP recorded from 365 to 7 days before admission. Post-resuscitation MAP was median MAP during the 7th hour after initiating resuscitation.Entities:
Keywords: Blood pressure target; Early goal-directed therapy; Fluid resuscitation; Hypertension; Severe sepsis
Year: 2018 PMID: 30535664 PMCID: PMC6288098 DOI: 10.1186/s13613-018-0468-5
Source DB: PubMed Journal: Ann Intensive Care ISSN: 2110-5820 Impact factor: 6.925
Fig. 1Flow diagram. The chart shows patient inclusion and exclusion in the study. AKI indicates acute kidney injury; EGDT, early goal-directed therapy; ESRD, end-stage renal disease; MAP, mean arterial pressure; ΔMAP, pre-admission MAP minus the post-resuscitation
Patient characteristics, stratified by acute kidney injury status (N = 233)
| Patient characteristics | No AKI ( | AKI ( | |
|---|---|---|---|
| Age, median (IQR), year | 66.8 (56.0–80.8) | 72.8 (59.7–81.6) | .21 |
| Body mass index, median (IQR), kg/m2 | 25.2 (21.8–28.6) | 27.9 (23.2–33.1) | .01 |
| Male sex, No. (%) | 45 (61.6) | 83 (51.9) | .20 |
| Pre-admission MAP, median (IQR), mmHga | 83.8 (76.0–91.5) | 78.5 (73.4–87.6) | .05 |
| MAP at first hour of admission, median (IQR), mmHg | 67.5 (59.0–78.0) | 65.0 (57.0–73.3) | .1 |
| MAP at first hour of resuscitation, median (IQR), mmHg | 62.3 (57.0–73.3) | 63.0 (55.8–70.9) | .2 |
| Post-resuscitation MAP, median (IQR), mmHgb | 71.0 (66.0–79.0) | 66.0 (61.0–73.0) | .01 |
| ΔMAP from Baseline to 7th hour of resuscitation, median (IQR), mmHgc | 11.0 (0.5–20.3) | 12.4 (5.7–19.8) | .31 |
| Charlson comorbidity index, median (IQR) | 6 (4–8.5) | 7 (5–11) | .02 |
| APACHE III score, 24 h, median (IQR) | 67 (55.5–79) | 88 (72–103) | .01 |
| SOFA score, day 1, median (IQR) | 5 (3–7) | 7 (5–10.8) | .01 |
| Culture positive septic shock (%) | 31 (42) | 85 (53) | .2 |
| Positive culture source | .7 | ||
| Blood (%) | 7 (10) | 20 (13) | |
| Urine (%) | 5 (7) | 19 (12) | |
| Respiratory (%) | 16 (22) | 33 (20) | |
| Wound (%) | 1 (1) | 6 (4) | |
| Other (%) | 2 (2) | 7 (4) | |
| Culture negative septic shock (%) | 42 (58) | 75 (47) | .2 |
| Preexisting condition, No. (%) | |||
| Hypertension | 38 (52.1) | 115 (71.9) | .01 |
| Myocardial infarction | 10 (13.7) | 39 (24.4) | .08 |
| Congestive heart failure | 8 (11.0) | 37 (23.1) | .03 |
| Peripheral vascular disease | 3 (4.1) | 25 (15.6) | .02 |
| Dementia | 5 (6.8) | 7 (4.4) | .52 |
| Cerebrovascular accident | 6 (8.2) | 34 (21.3) | .01 |
| Chronic pulmonary disease | 16 (21.9) | 54 (33.8) | .09 |
| Rheumatic heart disease | 8 (11.0) | 15 (9.4) | .81 |
| Diabetes mellitus | 15 (20.5) | 61 (38.1) | .01 |
| Peptic ulcer disease | 6 (8.2) | 20 (12.5) | .38 |
| Cirrhosis | 4 (5.5) | 10 (6.3) | > .99 |
| Hemiplegia | 4 (5.5) | 3 (1.9) | .21 |
| Kidney disease | 10 (13.7) | 45 (28.1) | .02 |
| Brittle diabetes mellitus | 4 (5.5) | 26 (16.3) | .02 |
| Cancer | 28 (38.4) | 49 (30.6) | .29 |
| Leukemia | 1 (1.4) | 9 (5.6) | .18 |
| Lymphoma | 2 (2.7) | 8 (5.0) | .73 |
| Moderate or severe liver disease | 3 (4.1) | 5 (3.1) | .71 |
| Metastatic cancer | 7 (9.6) | 14 (8.8) | .81 |
| Any inotropic agent, No. (%) | 4 (5.5) | 28 (17.5) | .01 |
| Any vasoactive agent, No. (%) | 32 (43.8) | 108 (67.5) | .01 |
| Fluid balance, median (IQR), mL | 4945 (2019–8282) | 6948 (3658–10,810) | .01 |
APACHE acute physiology, age, chronic health evaluation, MAP mean arterial pressure, SOFA sequential organ failure assessment
aFrom noninvasive blood pressure monitoring
bSeventh hour of early goal-directed therapy
cDefined as pre-admission minus post-resuscitation MAP
Comparison of patients in quartile 1 versus quartiles 2–4 of delta mean arterial pressure (N = 233)
| Characteristic | Quartile 1 ( | Quartiles 2–4 ( | |
|---|---|---|---|
| Age, median (IQR), year | 66.3 (55.7–79.9) | 72.1 (59.4–81.7) | .60 |
| Body mass index, median (IQR), kg/m2 | 27.8 (23.7–32.8) | 26.8 (22.2–31.6) | .23 |
| Male sex, No. (%) | 32 (55.2) | 96 (54.9) | > .99 |
| Pre-admission MAP, median (IQR), mmHga | 73.9 (67.8–81.9) | 82.0 (76.3–91.0) | .01 |
| Post-resuscitation MAP, median (IQR), mmHgb | 79.0 (70.5–87.1) | 66.0 (61.0–71.0) | .01 |
| Acute kidney injury, No. (%) | 33 (56.9) | 127 (72.6) | .03 |
| Stage 1 | 13 (17.8) | 60 (82.2) | |
| Stage 2 | 14 (26.0) | 40 (74.1) | |
| Stage 3 | 6 (18.2) | 27 (81.8) | |
| Charlson comorbidity index, median (IQR) | 7 (4.8–10.3) | 7 (5.0–10.0) | .55 |
| APACHE III score, 24 h, median (IQR) | 78 (64.8–97.3) | 82 (66–97) | .66 |
| SOFA score, day 1, median (IQR) | 6 (4–9) | 7 (4–10) | .76 |
| Culture positive septic shock (%) | 29 (50) | 87 (50) | .96 |
| Positive culture source | .5 | ||
| Blood (%) | 5 (9) | 22 (13) | |
| Urine (%) | 5 (9) | 19 (11) | |
| Respiratory (%) | 16 (28) | 33 (19) | |
| Wound (%) | 2 (3) | 5 (3) | |
| Other (%) | 1 (1) | 8 (4) | |
| Culture negative septic shock (%) | 29 (50) | 88 (50) | .96 |
| Preexisting condition, No. (%) | |||
| Hypertension | 36 (62.1) | 117 (66.9) | .53 |
| Myocardial infarction | 11 (19.0) | 38 (21.7) | .71 |
| Congestive heart failure | 16 (27.6) | 29 (16.6) | .08 |
| Peripheral vascular disease | 5 (8.6) | 23 (13.1) | .49 |
| Dementia | 0 (0) | 12 (6.9) | .04 |
| Cerebrovascular accident | 9 (15.5) | 31 (17.7) | .84 |
| Chronic pulmonary disease | 16 (27.6) | 54 (30.9) | .74 |
| Rheumatic heart disease | 7 (12.1) | 16 (9.1) | .61 |
| Diabetes mellitus | 22 (37.9) | 54 (30.9) | .34 |
| Peptic ulcer disease | 7 (12.1) | 19 (10.9) | .81 |
| Cirrhosis | 2 (3.4) | 12 (6.9) | .53 |
| Hemiplegia | 5 (8.6) | 2 (1.1) | .01 |
| Kidney disease | 14 (24.1) | 41 (23.4) | > .99 |
| Brittle diabetes mellitus | 7 (12.1) | 23 (13.1) | > .99 |
| Cancer | 19 (32.8) | 58 (33.1) | > .99 |
| Leukemia | 3 (5.2) | 7 (4.0) | .71 |
| Lymphoma | 7 (12.1) | 3 (1.7) | .01 |
| Moderate or severe liver disease | 2 (3.4) | 6 (3.4) | > .99 |
| Metastatic cancer | 6 (10.3) | 15 (8.6) | .79 |
| Any inotropic agent, No. (%) | 5 (8.6) | 27 (15.4) | .27 |
| Any vasoactive agent, No. (%) | 35 (60.3) | 105 (60.0) | > .99 |
| Fluid balance, median (IQR), mL | 6405 (2141–9723) | 6102 (3210–9742) | .31 |
APACHE acute physiology, age, chronic health evaluation, MAP mean arterial pressure, SOFA Sequential organ failure assessment
aFrom noninvasive blood pressure monitoring
bSeventh hour of early goal-directed therapy
Regression model for prediction of acute kidney injury for all patients
| Characteristic | Odds ratio | 95% confidence interval | |
|---|---|---|---|
| Being in the first quartilea | 0.26 | 0.11–0.57 | .01 |
| Body mass index | 0.92 | 0.87–0.96 | .01 |
| APACHE III score, 24 h | 0.96 | 0.94–0.97 | .01 |
| Pre-admission MAP | 1.04 | 1.01–1.08 | .01 |
APACHE acute physiology, age, chronic health evaluation, MAP mean arterial pressure
aPatients had ΔMAP values in the lowest quartile
Patient characteristics, stratified by history of hypertension (N = 233)
| Characteristic | No hypertension ( | History of hypertension ( | |
|---|---|---|---|
| Age, median (IQR), year | 62.5 (50.6–78.0) | 74.5 (63.4–82.6) | .01 |
| Body mass index, median (IQR), kg/m2 | 25.0 (21.2–28.7) | 28.0 (23.3–33.6) | .01 |
| Male sex, No. (%) | 45 (56.3) | 83 (54.2) | .78 |
| Pre-admission MAP, median (IQR), mmHga | 77.3 (72.1–87.3) | 81.3 (75.0–90.5) | .13 |
| Post-resuscitation MAP, median (IQR), mmHgb | 68.0 (62.2–76.5) | 68.0 (62.0–74.4) | .98 |
| ΔMAP, median (IQR), mmHgc | 11.3 (3.0–17.9) | 12.7 (4.0–21.0) | .18 |
| Acute kidney injury, No. (%) | 45 (56.3) | 115 (75.2) | .01 |
| Stage 1 | 25 (34.3) | 48 (65.8) | |
| Stage 2 | 12 (22.2) | 42 (77.8) | |
| Stage 3 | 8 (24.2) | 25 (75.8) | |
| Charlson comorbidity index, median (IQR) | 5 (3–7) | 8 (6–11) | .01 |
| APACHE III score, 24 h, median (IQR) | 71 (61.3–88.8) | 86 (69.5–103) | .01 |
| SOFA score, day 1, median (IQR) | 6 (4–9) | 7 (4–10) | .40 |
| Any inotropic agent, No. (%) | 8 (10.0) | 24 (15.7) | .32 |
| Any vasoactive agent, No. (%) | 46 (57.5) | 94 (61.4) | .58 |
| Fluid balance, median (IQR), mL | 6419 (3334–8953) | 6073 (2398–10,225) | .43 |
APACHE acute physiology, age, chronic health evaluation, MAP mean arterial pressure, SOFA Sequential organ failure assessment
aFrom noninvasive blood pressure monitoring
bSeventh hour of early goal-directed therapy
cDefined as pre-admission minus post-resuscitation MAP
Comparison of patients with hypertension in quartile 1 versus quartiles 2–4 of delta mean arterial pressure (n = 153)
| Characteristic | First quartile ( | Second to fourth quartiles ( | |
|---|---|---|---|
| Age, median (IQR), year | 73.7 (55.9–80.7) | 74.8 (64.2–83.1) | .14 |
| Body mass index, median (IQR), kg/m2 | 28.6 (23.9–34.1) | 27.9 (23.3–33.6) | .39 |
| Male sex, No. (%) | 22 (56.4) | 61 (53.5) | .85 |
| Pre-admission MAP, median (IQR), mmHga | 75.0 (69.0–84.0) | 83.5 (76.7–91.3) | .01 |
| Post-resuscitation MAP, median (IQR), mmHgb | 79.0 (71.5–86.0) | 65.0 (61.0–70.3) | .01 |
| Acute kidney injury, No. (%) | 24 (61.5) | 91 (79.8) | .03 |
| Stage 1 | 9 (18.8) | 39 (81.3) | |
| Stage 2 | 10 (23.8) | 32 (76.2) | |
| Stage 3 | 5 (20.0) | 20 (80.0) | |
| Charlson comorbidity index, median (IQR) | 9 (6–12) | 7.5 (6–11) | .62 |
| APACHE III score, day 1, median (IQR) | 88 (72–99) | 85.5 (68.8–104.3) | .51 |
| SOFA score, day 1, median (IQR) | 6 (4–8) | 7 (4–10) | .28 |
| Preexisting condition, No. (%) | |||
| Myocardial infarction | 10 (25.6) | 31 (27.2) | > .99 |
| Congestive heart failure | 14 (35.9) | 25 (21.9) | .09 |
| Peripheral vascular disease | 5 (12.8) | 22 (19.3) | .47 |
| Dementia | 0 (0) | 10 (8.8) | .07 |
| Cerebrovascular accident | 8 (20.5) | 28 (24.6) | .67 |
| Chronic pulmonary disease | 12 (30.8) | 40 (35.1) | .70 |
| Rheumatic heart disease | 6 (15.4) | 10 (8.8) | .24 |
| Diabetes mellitus | 18 (46.2) | 48 (42.1) | .71 |
| Peptic ulcer disease | 6 (15.4) | 18 (15.8) | > .99 |
| Cirrhosis | 0 (0) | 8 (7.0) | .20 |
| Hemiplegia | 5 (12.8) | 2 (1.8) | .01 |
| Kidney disease | 13 (33.3) | 35 (30.7) | .84 |
| Brittle diabetes mellitus | 7 (17.9) | 20 (17.5) | > .99 |
| Cancer | 15 (38.5) | 36 (31.6) | .44 |
| Leukemia | 2 (5.1) | 4 (3.5) | .65 |
| Lymphoma | 4 (10.3) | 3 (2.6) | .07 |
| Moderate or severe liver disease | 0 (0) | 4 (3.5) | .57 |
| Metastatic cancer | 5 (12.8) | 10 (8.8) | .53 |
| Any inotropic agent, No. (%) | 3 (7.7) | 21 (18.4) | .13 |
| Any vasoactive agent, No. (%) | 24 (61.5) | 70 (61.4) | > .99 |
| Fluid balance, median (IQR), mL | 7193 (1349–10,280) | 5733 (2820–10,220) | .32 |
ΔMAP is defined as pre-admission minus post-resuscitation MAP
APACHE acute physiology, age, chronic health evaluation, MAP mean arterial pressure, SOFA sequential organ failure assessment
aFrom noninvasive blood pressure monitoring
bSeventh hour of early goal-directed therapy
Regression model for prediction of acute kidney injury for all patients with hypertension history
| Characteristic | Odds ratio | 95% confidence interval | |
|---|---|---|---|
| Being in the first quartilea | 0.12 | 0.04–0.37 | .01 |
| Body mass index | 0.90 | 0.84–0.96 | .01 |
| APACHE III score, 24 h | 0.97 | 0.95–0.99 | .01 |
| Pre-admission MAP | 1.07 | 1.01–1.12 | .01 |
| Brittle diabetes mellitus | 6.03 | 1.36–44.19 | .04 |
| Norepinephrine use | 3.72 | 1.42–10.54 | .01 |
APACHE acute physiology, age, chronic health evaluation, MAP mean arterial pressure
aPatients had ΔMAP values in the lowest quartile